Focused On-demand Library for Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9NPZ5

UPID:

B3GA2_HUMAN

Alternative names:

Beta-1,3-glucuronyltransferase 2; GlcAT-D; UDP-glucuronosyltransferase S

Alternative UPACC:

Q9NPZ5; Q5JS09; Q8TF38; Q96NK4

Background:

Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 2, also known as Beta-1,3-glucuronyltransferase 2, GlcAT-D, and UDP-glucuronosyltransferase S, plays a crucial role in the biosynthesis of L2/HNK-1 carbohydrate epitope on glycolipids and glycoproteins. This protein's activity is pivotal in the modification of cell surface molecules, influencing cell adhesion, migration, and interaction processes.

Therapeutic significance:

Understanding the role of Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 2 could open doors to potential therapeutic strategies. Its involvement in the biosynthesis of key carbohydrate epitopes suggests its potential impact on cellular communication and immune response, offering a promising avenue for research into novel drug targets.